Result of General Meeting

Result of General Meeting

London, 1 May 2014 Sinclair IS Pharma plc (AIM:SPH.L), the international specialty pharma company, announces that at a General Meeting of the Company held earlier today, the resolutions, as set out in the Notice of General Meeting annexed to the Circular to shareholders dated 15 April 2014, were duly passed. Admission represents the final condition to completion of the Acquisition and Proposed Placing.

It is expected that Admission will become effective at 8.00 a.m. on 2 May 2014. The Placing Shares, when issued and fully paid, will rank pari passu in all respects with the existing Ordinary Shares of 1p each.

Following Admission the total number of voting rights in Sinclair IS Pharma plc will be 497,414,773. The above figure 497,414,773 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Sinclair IS Pharma plc, under the Disclosure and Transparency Rules.

Ends

For further information please contact:

Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Robert Taylor

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Clare Terlouw

Notes to Editors:

About Sinclair IS Pharma plc - see www.sinclairispharma.com

Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology, in particular Aesthetics, Wound care, and Skin care. The Group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward‐looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward‐looking statements due to a variety of factors.